Nitrilase mediated mild hydrolysis of a carbon‐14 nitrile for the radiosynthesis of 4‐(7‐hydroxycarbamoyl‐[1‐14C‐heptanoyl]‐oxy)‐benzoic acid methyl ester, [14C]‐SHP‐141: A novel class I/II histone deacetylase (HDAC) inhibitor

Author:

Kitson Sean L.1ORCID,Watters William1,Moody Thomas S.12,Chappell Todd3,Mazitschek Ralph456

Affiliation:

1. Department of Technology Almac, 20 Seagoe Industrial Estate Craigavon UK

2. Arran Chemical Company Limited, Unit 1 Monksland Industrial Estate, Athlone, Co Roscommon Ireland

3. Shape Pharmaceuticals Inc Cambridge MA USA

4. Center for Systems Biology Massachusetts General Hospital Boston MA USA

5. Broad Institute of MIT and Harvard Cambridge MA USA

6. Harvard T.H. Chan School of Public Health Boston MA USA

Abstract

A strategy has been developed for the carbon‐14 radiosynthesis of [14C]‐SHP‐141, a 4‐(7‐hydroxycarbamoyl‐heptanoyloxy)‐benzoic acid methyl ester derivative containing a terminal hydroxamic acid. The synthesis involved four radiochemical transformations. The key step in the radiosynthesis was the conversion of the 7‐[14C]‐cyano‐heptanoic acid benzyloxyamide [14C]‐4 directly into the carboxylic acid derivative, 7‐benzyloxycarbamoyl‐[14C]‐heptanoic acid [14C]‐8 using nitrilase‐113 biocatalyst. The final step involved deprotection of the benzyloxy group using catalytic hydrogenation to facilitate the release of the hydroxamic acid without cleaving the phenoxy ester. [14C]‐SHP‐141 was isolated with a radiochemical purity of 90% and a specific activity of 190 μCi/mg from four radiochemical steps starting from potassium [14C]‐cyanide in a radiochemical yield of 45%.

Publisher

Wiley

Subject

Organic Chemistry,Spectroscopy,Drug Discovery,Radiology, Nuclear Medicine and imaging,Biochemistry,Analytical Chemistry

Reference15 articles.

1. National Cancer Institute.HDAC inhibitor SHP‐141.https://www.cancer.gov/publications/dictionaries/cancer-drug/def/remetinostat?redirect=true 2023.

2. BradnerJE MazitschekR.Histone Deacetylase Inhibitors (U.S. Patent No. WO2007095584).https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2007095584

3. Medivir.Remetinostat.https://www.medivir.com/our-projects/projects-for-licensing/remetinostat Tuesday 04 April2023.

4. Treatment of Cutaneous Squamous Cell Carcinoma With the Topical Histone Deacetylase Inhibitor Remetinostat

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3